Table 1. Preclinical outcome analysis of CDK4 and CDK6 inhibitors.
| Indication | Agent | Cell culture |
Animal model |
Markers | Clinical | Refs |
|---|---|---|---|---|---|---|
| Mantle cell lymphoma |
PD-0332991 | Yes | Yes | - | Yes | 165,187 |
| Acute lymphoblastic lymphoma |
PD-0332991 | Yes | Yes | - | - | 147,148 |
| Multiple myeloma |
PD-0332991 | Yes | Yes | - | Yes | 188 |
| Liposarcoma | PD-0332991 and LEE011 |
Yes | Yes | CDK4 | Yes | 159,166 |
| Hepatocellular carcinoma |
PD-0332991 | Yes | Yes | RB and p16INK4A | Yes | 153 |
| Ovarian cancer | PD-0332991 | Yes | Yes | RB and p16INK4A | Yes | 175 |
| Breast cancer | PD-0332991, LEE-011 |
Yes | Yes | RB, p16INK4A and luminal subtype |
Yes |
152,154, 155,169 |
| Lung adenocarcinoma |
PD-0332991 | Yes | Yes | - | Yes | 150,189 |
| Prostate cancer | PD-0332991 | Yes | Yes | - | Yes | 190 |
| Glioma | PD-0332991 | Yes | Yes | RB and p16INK4A | Yes | 156,191,192 |
| Renal cancer | PD-0332991 | Yes | Yes | RB and p16INK4A | 176 | |
| Melanoma | PD-0332991 and LY2835219 |
Yes | Yes | - | Yes | 183,193,194 |
| Medulloblastoma | PD-0332991 | Yes | Yes | - | - | 195 |
| Colon cancer | PD-0332991 | Yes | Yes | - | Yes | 150 |
| Oesophageal cancer |
PD-0332991 | Yes | - | - | - | 196 |
| Neuroblastoma | LEE011 | Yes | Yes | - | Yes | 157 |
| Pancreatic cancer | PD-0332991 | Yes | Yes | - | - | 184,197 |
CDK, cyclin-dependent kinase; RB, retinoblastoma protein.